Page last updated: 2024-09-04

febuxostat and Left Ventricular Dysfunction

febuxostat has been researched along with Left Ventricular Dysfunction in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Akasaki, Y; Eguchi, K; Fukumoto, Y; Kamiya, H; Kario, K; Kusunose, K; Node, K; Sata, M; Tanaka, A; Teragawa, H; Yamada, H; Yoshida, H	1
Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF	1
Bache, RJ; Chen, Y; Hu, X; Lu, Z; Wessale, JL; Xu, X; Zhang, P; Zhao, L	1

Trials

1 trial(s) available for febuxostat and Left Ventricular Dysfunction

Article	Year
Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study. Hypertension research : official journal of the Japanese Society of Hypertension, 2022, Volume: 45, Issue:1 Topics: Awards and Prizes; Diastole; Febuxostat; Humans; Hyperuricemia; Natriuretic Peptide, Brain; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left; Ventricular Function, Left	2022

Article

Year

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study.

Hypertension research : official journal of the Japanese Society of Hypertension, 2022, Volume: 45, Issue:1

Topics: Awards and Prizes; Diastole; Febuxostat; Humans; Hyperuricemia; Natriuretic Peptide, Brain; Randomized Controlled Trials as Topic; Ventricular Dysfunction, Left; Ventricular Function, Left

2022

Other Studies

2 other study(ies) available for febuxostat and Left Ventricular Dysfunction

Article	Year
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. Heart and vessels, 2020, Volume: 35, Issue:10 Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progression; Drug Prescriptions; Febuxostat; Female; Gout Suppressants; Heart Disease Risk Factors; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; Middle Aged; Protective Factors; Retrospective Studies; Risk Assessment; Stroke Volume; Time Factors; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2020
Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. Journal of cardiac failure, 2008, Volume: 14, Issue:9 Topics: Animals; Disease Models, Animal; Febuxostat; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Systole; Thiazoles; Ventricular Dysfunction, Left	2008

Article

Year

Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.

Heart and vessels, 2020, Volume: 35, Issue:10

Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progression; Drug Prescriptions; Febuxostat; Female; Gout Suppressants; Heart Disease Risk Factors; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; Middle Aged; Protective Factors; Retrospective Studies; Risk Assessment; Stroke Volume; Time Factors; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2020

Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice.

Journal of cardiac failure, 2008, Volume: 14, Issue:9

Topics: Animals; Disease Models, Animal; Febuxostat; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Systole; Thiazoles; Ventricular Dysfunction, Left

2008